search.noResults

search.searching

dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
EDITOR’S NOTES


On the High-Speed Train to the Future, Exciting Innovation of All Kinds


By Mark Hagland T Mark Hagland


he lightning-fast development of two COVID- 19 vaccines, both based on messenger RNA (mRNA) technology rather than on the injection


of a small amount of the virus itself, has been one of the most exciting and dramatic developments in medical science in recent decades. As Carolyn Y. Johnson wrote in the Washington Post on Dec. 6 of last year, “The world’s hopes have weighed heavily on the quest to develop coronavirus vaccines, with an espe- cially intense focus on two front-runners: one from Moderna, the other from Pfi zer and BioNTech. Both were a speedy but risky — even controversial — bet, based on a promising but still-experimental medical technology.” Fortunately, the bet paid off, and both vaccines received emergency approval from the Food and Drug Administration (FDA) and the go-ahead for distribution from the Centers for Disease Control


and Prevention (CDC) in December. As Johnson noted, “Vaccine development typically takes years, even decades. The progress of the last 11 months shifts the paradigm for what’s possible, creating a new model for vaccine development and a toolset for a world that will have to fi ght more never-before-seen viruses in years to come.” There is great promise in mRNA technology. As the CDC’s website explains, “mRNA


vaccines take advantage of the process that cells use to make proteins in order to trigger an immune response and build immunity to SARS-CoV-2, the virus that causes COVID-19. In contrast, most vaccines use weakened or inactivated versions or components of the disease-causing pathogen to stimulate the body’s immune response to create antibod- ies.” In contrast, “mRNA vaccines have strands of genetic material called mRNA inside a special coating, [which] protects the mRNA from enzymes in the body that would otherwise break it down,” and provides instructions for the cell on how to make a piece of the “spike protein” unique to COVID-19, without doing any harm. What’s interesting is that mRNA vaccine development is not new. The CDC notes that


“Early stage clinical trials using mRNA vaccines have been carried out for infl uenza, Zika, rabies, and cytomegalovirus (CMV). Challenges encountered in these early trials included the instability of free RNA in the body, unintended infl ammatory outcomes, and modest immune responses.” But, the agency notes, the technology has been improv- ing dramatically. Beyond vaccines, numerous preclinical and clinical studies have used mRNA to


encode cancer antigens to stimulate immune responses targeted at clearing or reducing malignant tumors. With regard to that, as Kelly Servick wrote in Science, published by the American


Association for the Advancement of Science (AAAS), online on Dec. 16, “[L]ong before the pandemic, mRNA tantalized pharma, promising a simple and fl exible way to deliver both vaccines and drugs. One mRNA sequence might mend a damaged heart by producing a protein that stimulates blood vessel growth. Another might encode a missing enzyme to reverse a rare genetic disease.” So, even as the United States and the world continue to reel from the deadly impact


of the coronavirus, scientists have rushed to deliver innovations to save the health, and lives, of billions around the world. Moving forward into the future remains challenging, as the leaders of hospitals, medi-


cal groups, and health systems continue forward in the face of the clinical, operational, and fi nancial impacts of the pandemic, and work to move forward into the emerging value-based healthcare system. What concrete steps are they taking? We share the results of our second annual State of the Industry Survey in our cover story (p. 8). What’s clear is that healthcare leaders see the need for innovative change and are moving forward to meet it. A challenging time in healthcare? Absolutely. But also, an exciting one.


2 hcinnovationgroup.com | JANUARY/FEBRUARY 2021


www.HCinnovationgroup.com EDITORIAL


Editor-in-Chief: Mark Hagland 917-275-2426


mhagland@HCinnovationgroup.com


Managing Editor: Rajiv Leventhal 212-812-1418


rleventhal@HCinnovationgroup.com


Senior Editor: David Raths draths@mac.com


ADVERTISING SALES


Publisher: Matt Raynor 561-776-0015


mraynor@HCinnovationgroup.com


Sales Director: Anita Brodersen 847-744-2884


abrodersen@HCinnovationgroup.com


Sales Director: Steve Menc 814-450-5571


smenc@HCinnovationgroup.com


Events Program Director: Stephen McCollum smccollum@HCinnovationgroup.com SERVICES


Graphic Artist: Patti Connors pconnors@endeavorb2b.com


Ad Traffi c Manager: Tiffany Coffman tcoffman@endeavorb2b.com


Sr. Client Relationship Manager: Casie McAllister cmcallister@hcinnovationgroup.com


eProduct Coordinator: Mary Haberstroh mhaberstroh@endeavorb2b.com


List Rentals/Ad Contracts Mgr: Laura Moulton lmoulton@endeavorb2b.com


Single Back Issues/Subscriptions: subscriptions@endeavorb2b.com


GROUP PUBLISHER


Amy Mularski EVP, Healthcare Group amularski@HCinnovationgroup.com


CORPORATE TEAM


CEO Chris Ferrell


CRO/CMO June Griffin CFO William Nurthen COO Patrick Rains


Chief Administrative and Legal Officer Tracy Kane EVP Special Projects Kristine Russell EVP Key Accounts Scott Bieda


331 54th Ave N., Nashville, TN 37209 Phone: (941) 388-7050 Fax: (941) 388-7490 www.HCinnovationGroup.com


Healthcare Innovation content is also available from PROQUEST Information and Learning, 300 N. Zeeb Road, Ann Arbor, MI 48106 USA, 313-761-4700. Copyright Clearance Center, Inc. 978-750-8400.


Publishers of this magazine assume no responsibility for statements made by their advertisers in business competition, nor do they assume responsibility for statements/opinions expressed or implied in the columns of this magazine. Printed in the USA.


HEALTHCARE INNOVATION formerly Health Management Technology


(ISSN 2641-7502)


Published bi-monthly by Endeavor Business Media, LLC., 2477 Stickney Point Rd., Suite 221B Sarasota, FL 34231, (941) 388-7050.


Subscription rates: $52.80 per year in the United States; $64.90 Canada/ Mexico; International subscriptions are $95.15 per year. Current single copies (if available) are $15.40 each (U.S), and $19.80 each (international). Back is- sues (if available) are $17.60 each (U.S.) and $22 each (International). Payment must be made in U.S. funds on a branch of a U.S. bank within the continental United States and accompany request. Subscription inquiries: subscriptions@ endeavorb2b.com.


Title registered U.S. Patent Offi ce. Copyright 2021 by Endeavor Business Media, LLC., All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, includ- ing photocopy, recording, or any information storage-and-retrieval system, without permission in writing from the publisher.


Offi ce of publication: Periodicals Postage Paid at Nashville, TN 37209 and at additional mailing offi ces. Postmaster: Send address changes to Omeda (Healthcare Innovation), PO Box 3257, Northbrook, IL 60065-3257.


facebook.com//healthcareinnovationgroup twitter.com /hcinnovationgrp linkedin.com /groups/90501/


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32